Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged \>= 6 months to \< 9 years at the time of the first study vaccination.~* For children \< 3 years of age at the time of first vaccination, born at or after 36 weeks of gestation.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- CSL425 (15 mcg) (Type: EXPERIMENTAL): 15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
- CSL425 (30 mcg) (Type: EXPERIMENTAL): 30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).